Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada

NEWTOWN SQUARE, Pa., April 3 /PRNewswire/ -- After more than a decade of
research and development, Kibow Biotech, Inc. announced today the launch of
Kibow Biotics(R), the Company's new patented and proprietary probiotic
formulation targeting kidney health. This product will be sold exclusively
through their online store. Maintaining healthy kidney function is a concern
for over 200 million people worldwide. Despite this need, complementary and
alternative solutions have not been readily available, until now! Based on a
patented platform technology, Kibow Biotics uses the bowel to augment kidney
function.

Kibow Biotics will be made available initially in the U.S.
(http://www.kibow.com) and in Canada (http://www.gelda.com). The product is a
dietary supplement and not a drug; it is not intended to be used as a drug or
as a substitute for any drug application. The Company encourages referrals
from healthcare professionals, even though Kibow Biotics is a non-prescription
product.

Dr. Natarajan Ranganathan, Interim CEO and Senior VP (R&D), stated, "As per
U.S. FDA and FTC regulations, we cannot refer directly or indirectly to our
product formulation with words like 'disease,' 'drug,' 'therapy,' 'prevent,'
'cure,' 'delay,' 'eliminate,' 'remove' or 'mitigate' any symptoms or
illnesses. However, in spite of the stipulations we encounter in communicating
their benefits, probiotics are increasingly well-accepted. In fact, there are
hundreds of dietary supplements available over the counter (OTC) in health
food stores and through various other distribution channels in the USA, in
Canada and in several other countries. We are delighted that Kibow Biotics
will represent new hope and significant savings for maintaining kidney health,
initially in North America and Canada and progressively in other parts of the
world."

The latest in the Kibow family of scientifically developed and clinically
tested dietary supplements, Kibow Biotics contains three distinct strains of
carefully researched and specifically selected beneficial microbes
(probiotics) that possess a high affinity for various nitrogenous waste
products. The microbes metabolize the waste products and use them as nutrients
for growth. As the microbes grow and replicate, they create colonies capable
of utilizing even more nitrogenous waste products, which are then eliminated
as solid waste.

Kibow Biotics is composed of naturally occurring beneficial probiotic strains:
S. thermophilus (KB-19), L. acidophilus (KB-27), B. longum (KB-31), combined
with a dietary fiber (psyllium husk). Presented in an enteric-coated,
gluten-free, vegetarian gel capsule, each serving of Kibow Biotics contains a
total of 30 billion colony forming units (CFU).

When taken orally after every meal (3 times) on a daily basis, Kibow Biotics
has the potential to help maintain healthy kidney function. A multi-site,
6-month, double-blind, placebo-controlled, cross-over human clinical trial is
already complete in Canada. Similar clinical trials are still in progress in
USA, Mexico, Argentina and Nigeria. The development of Kibow Biotics has been
made possible through partial federal funding obtained in the form of two
National Institutes of Health (NIH) fast-track SBIR grants from the National
Institute of Diabetes, Digestive and Kidney Disease (NIDDK). Additional
support has been provided by USAID (funded through ICICI Bank, in Mumbai,
India).

For more information, visit http://www.kibow.com